300 related articles for article (PubMed ID: 25837259)
1. Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Mukhopadhyay KD; Liu Z; Bandyopadhyay A; Kirma NB; Tekmal RR; Wang S; Sun LZ
PLoS One; 2015; 10(4):e0121136. PubMed ID: 25837259
[TBL] [Abstract][Full Text] [Related]
2. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
5. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
6. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
7. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Yamaguchi Y; Takei H; Suemasu K; Kobayashi Y; Kurosumi M; Harada N; Hayashi S
Cancer Res; 2005 Jun; 65(11):4653-62. PubMed ID: 15930283
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
9. Estrogen metabolites and breast cancer.
Santen RJ; Yue W; Wang JP
Steroids; 2015 Jul; 99(Pt A):61-6. PubMed ID: 25168343
[TBL] [Abstract][Full Text] [Related]
10. Aromatase expression in ovarian epithelial cancers.
Cunat S; Rabenoelina F; Daurès JP; Katsaros D; Sasano H; Miller WR; Maudelonde T; Pujol P
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):15-24. PubMed ID: 15748828
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
12. Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Chottanapund S; Van Duursen MB; Navasumrit P; Hunsonti P; Timtavorn S; Ruchirawat M; Van den Berg M
Toxicol In Vitro; 2014 Oct; 28(7):1215-21. PubMed ID: 24929094
[TBL] [Abstract][Full Text] [Related]
13. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
14. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen formation in breast: clinical and biological importance.
Dowsett M; Detre S; Rowlands M; Grimshaw R
J Endocrinol; 1996 Sep; 150 Suppl():S59-63. PubMed ID: 8943788
[TBL] [Abstract][Full Text] [Related]
16. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
17. Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Hayashi S; Yamaguchi Y
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):201-6. PubMed ID: 18424035
[TBL] [Abstract][Full Text] [Related]
18. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
19. Regulation of aromatase expression in breast cancer tissue.
Bulun SE; Lin Z; Zhao H; Lu M; Amin S; Reierstad S; Chen D
Ann N Y Acad Sci; 2009 Feb; 1155():121-31. PubMed ID: 19250199
[TBL] [Abstract][Full Text] [Related]
20. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
